Merck Sharp + Dohme Corp.

Lycera Corporation

Catherine M White

Nunzio Sciammetta

Kun Liu

Thomas Daniel Aicher

Kenneth Jay Barr

Vladimir Simov

Yongxin Han

Hongjun Zhang

Matthew H Daniels

Blair T Lapointe

Meredeth Ann McGowan

Hua Zhou

William L Thomas

Brian M Andresen

Xavier Fradera

Chad A VanHuis

John K MacLean

Corey E Bienstock

Yuan Liu

Neville J Anthony

David L Sloman

Derun Li

Abdelghani Achab

Wensheng Yu

Kevin J Wilson

Craig R Gibeau

Brett A Hopkins

David James Witter

Xianhai Huang

Jongwon Lim

Peter Laurence Toogood

Phieng Siliphaivanh

Michelle R Machacek

Joshua Close

Yongqi Deng

Chad A Van Huis

Karin Ann Stein

Joseph A Kozlowski

Tesfaye Biftu

Stephane L Bogen

Jason D Brubaker

Feroze Ujjainwalla

Zhicai Wu

Ping Liu

Christopher W Boyce

Jonathan R Young

Raman Kumar Bakshi

Purakkattle J Biju

Ryan D Otte

Andrew M Haidle

Umar Faruk Mansoor

Joon Jung

Tony Siu

Michael Hale Reutershan

Lei Chen

Christian Fischer

Charles A Lesburg

Matthew Lloyd Childers

Jonathan B Grimm

John W Lampe

Peter H Fuller

Wei Zhou

Qinglin Pu

Min K Park

Ron Ferguson

Pengcheng Patrick Shao

Dann LeRoy Parker, Jr

Francesc Xavier Fradera Llinas

Matthew A Larsen

Salem Fevrier

Brandon D Cash

Michelle Martinez

Kake Zhao

Rachel Nicola MacCoss

Eric Thomas Romeo

Danielle Falcone

Brendan O'Boyle

Shuyi Tang

Kathryn Ann Lipford

Chunhui Huang

Alexander J Kim

Indu T Bharathan

Ravi Kurukulasuriya

Yang Yu

Judson E Richard

Qingmei Hong

J Michael Ellis

Ganesh Babu Karunakaran

Angie R Angeles

Sulagna Sanyal

Xin Yan

Sara Esposite

Wenlang Fu

Daniel R McMasters

Wesley B Trotter

Gabriela De Almeida

Meredeth A Mcgowan

George Madalin Giambasu

Valdimir Simov

Chad Van Huis

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.

IL4I1 inhibitors and methods of use

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted pyridinyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X, X, R, R, R, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT. 

Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof:  Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers. 

Tricyclic compounds as inhibitors of mutant IDH enzymes

The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting ROR&#x3b3; activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.

Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease

The invention provides certain bicyclic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X, X, R, R, R, R, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT. 

The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof wherein R, R, R, R, R, R, R, R, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT. 

Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease

The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT. 

2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease

Tetrahydronaphthyridine and related bicyclic compounds for inhibition of ROR&#x3b3; activity and the treatment of disease

Growing community of inventors

Newton Center, MA, United States of America

Catherine M White